The lipidome in nonalcoholic fatty liver disease: actionable targets

The lipidome in nonalcoholic fatty liver disease: actionable targets

Nonalcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease. Recent technological advances, combined with OMICs experiments and explorations involving different biological samples, have uncovered vital aspects of NAFLD biology. In this review, we summarize recent wor...

Full description

Bibliographic Details
Main Authors:	Carlos J. Pirola, Silvia Sookoian
Format:	Article
Language:	English
Published:	Elsevier 2021-01-01
Series:	Journal of Lipid Research
Subjects:	lipidomics NAFLD NASH butanoate microbiome systems biology
Online Access:	http://www.sciencedirect.com/science/article/pii/S0022227521000559

Similar Items

Nonalcoholic Fatty Liver Disease Progresses into Severe NASH when Physiological Mechanisms of Tissue Homeostasis Collapse
by: Silvia Sookoian, et al.
Published: (2018-03-01)

Nonalcoholic fatty liver disease stratification by liver lipidomics
by: Olga Vvedenskaya, et al.
Published: (2021-01-01)

Non-alcoholic fatty liver and the gut microbiota
by: Stavros Bashiardes, et al.
Published: (2016-09-01)

Impact of Nutritional Changes on Nonalcoholic Fatty Liver Disease
by: Carolina M. Perdomo, et al.
Published: (2019-03-01)

Nonalcoholic fatty liver disease and its association with cardiovascular disease
by: Javier Lizardi-Cervera, et al.
Published: (2009-01-01)

Genetic predisposition in nonalcoholic fatty liver disease
by: Silvia Sookoian, et al.
Published: (2017-03-01)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
by: Koichiro Wada, et al.
Published: (2013-11-01)

Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)
by: Sebastião M.B. Duarte, et al.
Published: (2019-05-01)

Exercise Training as Treatment of Nonalcoholic Fatty Liver Disease
by: Oliver K. Glass, et al.
Published: (2017-09-01)

Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut–Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy
by: Francesca Fianchi, et al.
Published: (2021-06-01)

SMN Depleted Mice Offer a Robust and Rapid Onset Model of Nonalcoholic Fatty Liver DiseaseSummary
by: Marc-Olivier Deguise, et al.
Published: (2021-01-01)

Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease
by: Soichi Iritani, et al.
Published: (2020-11-01)

Magnetic resonance‐based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
by: Cyrielle Caussy, et al.
Published: (2020-10-01)

The Presence and Severity of Nonalcoholic Steatohepatitis Is Associated with Specific Changes in Circulating Bile Acids
by: Aline Gottlieb, et al.
Published: (2018-05-01)

Treatment regimens for non-alcoholic fatty liver disease
by: Brian P. Lam, et al.
Published: (2009-01-01)

Modifying macronutrients is superior to microbiome transplantation in treating nonalcoholic fatty liver disease
by: Fontini Tania Mitsinikos, et al.
Published: (2020-11-01)

Detection of patatin-like phospholipase domain-containing protein 3 in nonalcoholic fatty liver disease among egyptian patients
by: Kadry M El Saeed, et al.
Published: (2019-01-01)

The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease
by: Sanjoy Roychowdhury, et al.
Published: (2018-06-01)

Hepatic Lrp1 deficiency and the development of nonalcoholic fatty liver disease
by: Hamlin, Allyson
Published: (2017)

Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis
by: Abdulrahman Ismaiel, et al.
Published: (2021-07-01)

Nonalcoholic fatty liver disease in asymptomatic obese women(a)(a)The work was originated in the Biomedical Research Unit of The Mexican Social Security Institute at Durango, Mex.
by: Heriberto Rodriguez-Hernandez, et al.
Published: (2010-04-01)

Hepatic Lipidomics and Molecular Imaging in a Murine Non-Alcoholic Fatty Liver Disease Model: Insights into Molecular Mechanisms
by: Ricardo Rodríguez-Calvo, et al.
Published: (2020-09-01)

Natural Product Heme Oxygenase Inducers as Treatment for Nonalcoholic Fatty Liver Disease
by: David E. Stec, et al.
Published: (2020-12-01)

Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH
by: Nikolaos Perakakis, et al.
Published: (2021-06-01)

Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH)
by: KyeongJin Kim, et al.
Published: (2020-03-01)

The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease
by: Umair Iqbal, et al.
Published: (2019-03-01)

A New Score Unveils a High Prevalence of Mild Cognitive Impairment in Patients with Nonalcoholic Fatty Liver Disease
by: Carla Giménez-Garzó, et al.
Published: (2021-06-01)

Epigenome-Wide Association Studies Provide Insight into the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
by: Aybike Birerdinc, et al.
Published: (2018-01-01)

Type IV collagen as marker of fibrosis in nonalcoholic liver disease
by: Alvina
Published: (2010-08-01)

Type IV collagen as marker of fibrosis in nonalcoholic liver disease
by: Alvina Alvina
Published: (2016-02-01)

Role of MicroRNAs in Pathophysiology of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
by: Farzaneh Iravani, et al.
Published: (2018-10-01)

Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease
by: Myriam Alexander, et al.
Published: (2018-08-01)

Renal resistive index in non-alcoholic fatty liver disease as an indicator of early renal affection
by: Hossam El-Din A. Mahmoud, et al.
Published: (2020-02-01)

Protective effect of genistein on nonalcoholic fatty liver disease (NAFLD)
by: Xin Xin, et al.
Published: (2019-09-01)

Nonalcoholic fatty liver disease in Brazil. Clinical and histological profile
by: Helma P. Cotrim, et al.
Published: (2011-01-01)

Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatic Cytochrome P450 (CYP) Enzymes
by: Rohitash Jamwal, et al.
Published: (2020-08-01)

Metabolomic Predictors of Non-alcoholic Steatohepatitis and Advanced Fibrosis in Children
by: Kattayoun Kordy, et al.
Published: (2021-08-01)

Non-alcoholic fatty liver disease and microRNAs expression, how it affects the development and progression of the disease
by: Guillermo Nahúm López-Sánchez, et al.
Published: (2021-03-01)

Eicosanoids in Nonalcoholic Fatty Liver Disease (NAFLD) Progression. Do Serum Eicosanoids Profile Correspond with Liver Eicosanoids Content during NAFLD Development and Progression?
by: Dominika Maciejewska, et al.
Published: (2020-04-01)

Diagnosis and Staging of Pediatric Non-Alcoholic Fatty Liver Disease: Is Classical Ultrasound the Answer?
by: Angeliki Papachristodoulou, et al.
Published: (2021-06-01)